Recently, an everolimus-eluting stent utilizing a bioresorbabale PLA polymer coating to release the agent everolimus has proven safe and effective in preventing restenosis for up to six months in de novo coronary arteries. But the use of a bioresorbable polymer-coated everolimus-eluting stent for in-stent restenosis lesions has not been previously investigated. This is a case report of one-year angiographic follow-up results after the implantation of a bioresorbable PLA polymer-coated everolimus-eluting stent for the treatment of recurrent in-stent restenosis. The case involved a 63-year-old female who had repeatedly presented with recurrent in-stent restenosis in the LCX. We successfully treated this recurrent ISR lesion by using a bioresorbable PLA polymer-coated everolimus-eluting stent; the one-year follow-up angiography revealed prevention of ISR after the implantation of this device.
Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
A Randomized Comparison of Bioheart Sirolimus-Eluting Bioresorbable Scaffold and Everolimus-Eluting Stents: The BIOHEART-II Trial.
JACC Cardiovasc Interv
January 2025
Department of Cardiology, Fu Wai Hospital, National Center for Cardiovascular Diseases of China, Beijing, China. Electronic address:
Background: First-generation bioresorbable scaffolds (BRS) increased risks of stent thrombosis and adverse events. The Bioheart scaffold is a new poly-L-lactic acid-based BRS.
Objectives: This study sought to evaluate the efficacy and safety of the BRS in patients with coronary artery disease.
Early and Late Outcomes With the Absorb Bioresorbable Vascular Scaffold: Final Report From the ABSORB Clinical Trial Program.
JACC Cardiovasc Interv
January 2025
Zena and Michael A. Wiener Cardiovascular Institute, Icahn School of Medicine at Mount Sinai, New York, New York, USA. Electronic address:
Background: The risk-benefit ratio of the Absorb bioresorbable vascular scaffold (BVS) may vary before and after 3 years, the time point of complete bioresorption of the poly-L-lactic acid scaffold.
Objectives: The aim of this study was to determine the time-varying outcomes of the Absorb BVS compared with cobalt-chromium everolimus-eluting stents (EES) from a large individual-patient-data pooled analysis of randomized trials.
Methods: The individual patient data from 5 trials that randomized 5,988 patients undergoing percutaneous coronary intervention to the Absorb BVS vs EES with 5-year follow-up were pooled.
Polymer-free versus biodegradable-polymer drug-eluting stent in patients undergoing percutaneous coronary intervention: an assessor-blind, non-inferiority, randomised controlled trial.
EuroIntervention
January 2025
Department of Advanced Biomedical Sciences, University of Naples "Federico II", Naples, Italy.
Background: Few data are available on polymer-free drug-eluting stents in patients undergoing percutaneous coronary intervention (PCI).
Aims: We aimed to determine the efficacy and safety of a polymer-free amphilimus-eluting stent (AES), using a reservoir-based technology for drug delivery, compared with a biodegradable-polymer everolimus-eluting stent (EES).
Methods: This was a randomised, investigator-initiated, assessor-blind, non-inferiority trial conducted at 14 hospitals in Italy (ClinicalTrials.
Impact of coronary artery tortuosity on outcomes following stenting with newer-generation drug-eluting stents. An analysis of the randomized BIOFLOW trials.
Rev Esp Cardiol (Engl Ed)
January 2025
Department of Cardiology, Internal Medicine II, Medical University of Vienna, Vienna, Austria. Electronic address:
Introduction And Objectives: Patients undergoing percutaneous coronary intervention in vessels with moderate-to-severe tortuosity are at higher risk of adverse outcomes, but data are scarce in the era of newer-generation stents. We compared outcomes following percutaneous coronary intervention in vessels with moderate-to-severe tortuosity using a bioresorbable-polymer sirolimus-eluting stent (BP-SES) vs a durable-polymer everolimus-eluting stent.
Methods: A total of 2350 patients from the BIOFLOW II, IV, and V randomized trials were stratified into 2 groups based on target-vessel tortuosity: none-to-mild and moderate-to-severe.
Preclinical evaluation of the sirolimus-eluting iron bioresorbable scaffold in canine below-the-knee artery.
Int J Cardiol
February 2025
Department of Vascular and Endovascular Surgery, First Medical Center of Chinese PLA General Hospital, Beijing 100853, China. Electronic address:
Article Synopsis
- This study investigates the effectiveness of bioresorbable scaffolds (IBS) versus everolimus-eluting stents (EES) for treating below-the-knee arterial disease in dogs, focusing on their support performance and effects on tissue.
- Both types of implants were successfully used, showing similar levels of arterial narrowing within the first six months, but the IBS scaffold exhibited gradual corrosion over time.
- Overall, the findings indicate that the IBS is comparable to EES in terms of support and tissue response within 6 months, while demonstrating a manageable corrosion profile over a year.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!